Vaccine Wins And Biotech Dealmaking
Kilder
- STAT: STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
- Endpoints: Sensible Bio secures $47M Series A for mRNA therapy manufacturing platform
- BioPharma Dive: How AI is transforming biopharma manufacturing facilities of the future
- Labiotech: The biggest biotech funding rounds in September 2026
- STAT: STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
- STAT: Lilly’s Jaypirca approved as first-line CLL therapy - STAT
- Endpoints: Shionogi to pay $2B for IntraBio, a commercial rare disease biotech
- Fiercepharma: Shionogi strikes $2B deal for IntraBio hot off FDA label expansion - Fierce Pharma
- BioPharma Dive: Shionogi pays $2B to acquire a rare disease startup - BioPharma Dive
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.